CJC-1295 Research: DAC, No DAC, and Study Identity

CJC-1295 research is easy to misread when a product name is treated as a complete chemical identity. This guide examines two 2006 human reports and FDA's distinction between DAC and non-DAC substances. It is a selected-source guide, not a complete review of the current literature.

At a glance:

• Establish the studied molecule before interpreting its results.

• Changes in blood hormones are not the same as demonstrated health benefits.

• Findings for one construct do not validate a similarly named vial or blend.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. Source-access limits appear below.

1. What does DAC change in CJC-1295 research?

The early human work describes CJC-1295 as an analog, or modified version, of growth hormone-releasing hormone (GHRH). That identifies the research context; it does not establish the contents of a similarly named product. Clinical study context

DAC means drug affinity complex. FDA's December 2024 briefing distinguishes CJC-1295 from CJC-1295 DAC and their salt forms. It treats the DAC and non-DAC active molecules as non-interchangeable. The DAC modification permits chemical attachment to albumin, a protein in blood. FDA cautions against transferring the DAC construct's pharmacological profile to material without that modification. FDA briefing, identity and nonclinical sections — PDF

For a label saying “No DAC,” start with the reported sequence and modification details, not an assumed equivalence. This guide does not authenticate what any seller means by that label or verify the contents of our own inventory.

Removing a distinguishing word from a name cannot make the evidence transferable. A paper's methods and material description must match the substance being discussed.

2. What did the early healthy-adult trials measure?

Teichman and colleagues reported two randomized, double-blind, placebo-controlled trials lasting 28 and 49 days. Participants were healthy adults aged 21–61. The researchers measured growth hormone, or GH, and insulin-like growth factor I, or IGF-I, alongside the compound's behavior in the body. They reported sustained increases in these blood measurements and no serious adverse reactions in those trials. Teichman and colleagues, 2006 — abstract

That is evidence about measured hormonal responses in a defined study setting. It does not by itself establish improvements in sleep, physical function, or long-term health. A short trial reporting no serious reaction also cannot rule out uncommon or delayed harms.

An important reading habit is to keep the endpoint beside the finding. Here, the endpoint was largely a laboratory measurement, not a demonstrated everyday benefit. Avoid silently replacing one with the other.

3. Does preserved pulsatility mean an unchanged hormone pattern?

No. In a separate report, Ionescu and Frohman examined overnight GH measurements in healthy men before and one week after the albumin-binding construct. They found that pulse frequency and magnitude were unchanged, while the lowest levels between pulses and average GH increased. IGF-I also increased. Ionescu and Frohman, 2006 — abstract

A pulse is a temporary rise in hormone secretion; a trough is the lower level between rises. Keeping pulses does not mean every part of the pattern stayed unchanged. Nor does it demonstrate that a changed pattern is beneficial or safe for another population.

These two reports also share an investigator. They answer related but different questions and should not be described as two independent demonstrations of a general wellness benefit.

4. What safety context belongs beside the findings?

FDA's current compounding-risk page identifies immune-response and impurity-characterization concerns for CJC-1295. It also reports serious associated events, including increased heart rate and a body-wide blood-vessel dilation reaction, while noting limited clinical data. The entry is under withdrawn nominations. Withdrawal is not evidence that the safety concerns were resolved. FDA compounding safety context

This is compounding safety information, not a test of our catalog lots or a complete legal assessment of the storefront. Research-use wording is not scientific evidence of safety.

5. How can a reader avoid a false match?

Before attaching a study citation to a material record, check:

• Identity: the sequence, modifications, and chemical form are documented.

• Study: the material, population, comparison, and endpoint match the claim.

• Scope: uncertainty and unchanged outcomes are retained.

• Mixtures: evidence about separate ingredients is not presented as evidence about their combination.

For example, the two human reports discussed here concern CJC-1295, not a CJC-1295/ipamorelin blend. They do not demonstrate the performance of that mixture. This is a limit of these cited reports, not a claim that every possible combination study has been searched.

For document checks, use our COA, HPLC, and mass spectrometry guide and research peptide documentation checklist. Related reading is in the research resource library.

Review method and source access

Sources checked September 27, 2026: two original-study abstracts, selected sections of FDA's 2024 briefing, and FDA's current safety page. The full clinical papers, participant-level data, and complete funding disclosures were not reviewed. No new experiments or independent lot testing were performed. This is not a systematic review or regulatory clearance.

Catalog materials are offered for lawful laboratory research only, not for human or veterinary use. This article supplies no dosing or administration instructions and makes no claim that a current product reproduces a study's results.